IUI Treatment (Intrauterine Insemination) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Intrauterine insemination (IUI) is an assisted reproductive technique in which a prepared sample of sperm is deposited directly into the uterine cavity at the time of ovulation, bypassing the cervix to maximise the number of motile sperm reaching the fallopian tubes for fertilisation. It is among the simplest and least invasive forms of fertility treatment available and is often the first-line intervention offered before proceeding to in vitro fertilisation (IVF).

The procedure itself is straightforward: a thin, flexible catheter is guided through the cervix under ultrasound guidance (or by direct clinical feel), and a small volume (0.5 mL) of washed sperm is injected into the uterine cavity. The woman lies supine for approximately 10–15 minutes thereafter and is then free to return to normal activity. No anaesthetic is required, though mild cramping similar to period pain is common for a few hours afterwards.

IUI can be performed in two ways:

• Natural (unstimulated) IUI: The woman ovulates naturally. Ovulation is tracked using serial transvaginal ultrasound scans and urine or blood LH (luteinising hormone) monitoring. Insemination is timed to occur within 24–48 hours of the LH surge, which precedes ovulation by approximately 36 hours. This approach avoids the costs and risks of ovarian stimulation but produces only one follicle per cycle.
• Stimulated IUI: Low-dose ovarian stimulation with follicle-stimulating hormone (FSH) — given as daily subcutaneous injections — or oral clomifene citrate (clomiphene) is used to stimulate the development of one to three follicles. An hCG (human chorionic gonadotrophin) trigger injection then induces final follicular maturation and ovulation, and insemination is timed 36–40 hours later. Stimulation increases the number of eggs available for fertilisation but also increases the risk of multiple pregnancy if more than two mature follicles develop.

The key distinction between IUI and IVF is that in IUI, fertilisation occurs inside the body (in vivo) within the fallopian tube, just as it does in natural conception. IVF involves retrieving eggs surgically and fertilising them in the laboratory (in vitro) before transferring an embryo back to the uterus.

IUI is most effective when at least one fallopian tube is confirmed patent (open) and the female partner has adequate ovarian reserve. The principal clinical indications are:

Unexplained Infertility

Defined as failure to conceive after 12 months of regular unprotected intercourse in a couple where standard fertility investigations — semen analysis, tubal patency assessment, and ovarian reserve testing — are all normal. IUI offers a measured stepwise approach before IVF. NICE guideline NG156 (updated 2023) advises that unstimulated IUI is not recommended for unexplained infertility as it offers no benefit over expectant management, but that stimulated IUI may be offered as an intermediate step, particularly in NHS settings with access constraints for IVF.

Mild Male Factor Infertility

Where semen analysis reveals mildly reduced sperm count (oligospermia), motility (asthenospermia), or normal-form morphology (teratospermia) that fall above the threshold for IVF/ICSI consideration, IUI using the male partner's sperm after washing is an appropriate and cost-effective first-line treatment. IUI requires a post-wash total motile sperm count (TMSC) of at least 5–10 million to achieve reasonable success rates; below this threshold, direct IVF with ICSI is recommended.

Cervical Mucus Hostility

Sperm may be unable to penetrate the cervical mucus due to anti-sperm antibodies, previous cervical surgery (LLETZ/cone biopsy), or inadequate cervical mucus production. By depositing sperm directly into the uterine cavity, IUI bypasses the cervix entirely, making cervical factor irrelevant to fertilisation.

Donor Sperm Insemination (DI)

IUI is the standard method for using donor sperm in single women, same-sex female couples, or heterosexual couples where the male partner has no sperm (azoospermia) or carries a serious genetic condition. Donor sperm is sourced from licensed sperm banks (regulated by the HFEA in the UK, ASRM in the USA, etc.) and screened for infectious diseases and genetic conditions. IUI with donor sperm achieves per-cycle pregnancy rates of 10–18% — somewhat higher than with partner sperm, reflecting that donors are selected for optimal semen parameters.

Physical Barriers to Natural Intercourse

IUI may be appropriate for couples unable to achieve penetrative intercourse due to vaginismus, erectile dysfunction, hypospadias, or severe premature ejaculation, allowing conception using the male partner's sperm.

A structured fertility investigation must be completed before IUI is offered. Not all couples are suitable, and appropriate patient selection is critical to avoid delay of more effective treatment.

Tubal Patency Assessment (Mandatory)

IUI cannot succeed if both fallopian tubes are blocked, as fertilisation must occur in the tube. Tubal status is assessed by hysterosalpingography (HSG) — an X-ray procedure using contrast dye — or by hysterosalpingo-contrast sonography (HyCoSy) using ultrasound. At least one tube must be confirmed patent before IUI is offered.

Ovarian Reserve

Anti-Müllerian hormone (AMH) and antral follicle count (AFC) on transvaginal ultrasound are used to assess ovarian reserve. Very low AMH (<1.0 ng/mL) or AFC (<5–7 follicles) indicates diminished reserve, which reduces stimulated IUI success rates and may favour direct IVF. NICE NG156 advises against unstimulated IUI where ovarian response is likely to be poor.

Semen Analysis and Sperm Wash Results

A standard semen analysis (WHO 2021 reference criteria) is performed, followed by a trial sperm wash (density gradient centrifugation) to determine the post-wash total motile sperm count (TMSC). A TMSC of <5 million post-wash predicts a very low per-cycle IUI pregnancy rate and is a relative indication to proceed directly to IVF/ICSI.

Female Age

IUI success rates decline sharply with female age. Cumulative pregnancy rates of 30–40% over 3–6 cycles are achievable for women aged under 37 with favourable parameters. Above 37, per-cycle rates decline significantly, and NICE recommends that couples with female age over 40 proceed directly to IVF rather than IUI, to avoid wasting time on a less effective intervention.

Cycle Limit

Most UK NHS Clinical Commissioning Groups (now Integrated Care Boards) fund a maximum of 3–6 stimulated IUI cycles, depending on locality. Private clinics typically recommend a maximum of 6 cycles before reassessing and considering IVF, as cumulative benefit beyond 6 cycles is minimal.

The IUI process involves several coordinated steps, from cycle monitoring to sperm preparation and the insemination procedure itself.

Step 1: Cycle Monitoring

In unstimulated IUI, baseline transvaginal ultrasound (TVUSS) on cycle day 2–3 confirms the absence of ovarian cysts. Serial scans from day 10–12 track follicular growth. The natural LH surge — detected by urine LH tests at home (OPKs) or by serum LH measurement — triggers insemination timing, typically 24–36 hours after the LH peak is detected.

In stimulated IUI, low-dose FSH injections begin on cycle day 2–3. Serial ultrasound scans every 2–3 days monitor follicular development. When one to three dominant follicles reach 17–18 mm diameter, an hCG trigger injection (e.g. Pregnyl 5,000–10,000 IU, or Ovitrelle 250 mcg) induces final follicle maturation and ovulation. Insemination is scheduled 36–40 hours after the trigger. If more than three follicles develop, the cycle may be cancelled to avoid high-order multiple pregnancy.

Step 2: Sperm Preparation (Sperm Wash)

The sperm sample (either a fresh ejaculate produced at the clinic, or frozen-thawed donor sperm) is processed in the embryology laboratory by density gradient centrifugation: the semen is layered onto a density gradient medium and centrifuged, separating morphologically normal, progressively motile sperm from immotile sperm, debris, white blood cells, and seminal plasma. The recovered pellet is washed in culture medium to produce a small-volume concentrate of the highest-quality sperm. The process takes 60–90 minutes and typically recovers 60–80% of the progressively motile sperm from the original sample.

Step 3: Insemination

The patient empties her bladder (or has a partially full bladder per clinic protocol) and lies supine on the examination table. A speculum is inserted to visualise the cervix. A soft IUI catheter (e.g. Wallace or Frydman catheter) is gently passed through the cervical os into the uterine cavity under direct visualisation or ultrasound guidance. The prepared sperm sample (0.3–0.5 mL) is slowly injected over 30–60 seconds. The catheter is removed. The patient rests supine for 10–15 minutes. No anaesthetic is required; mild cramping is common and resolves quickly.

Step 4: Luteal Phase

Vaginal progesterone pessaries (400 mg twice daily) may be prescribed in stimulated cycles to support the luteal phase, particularly where hCG trigger was used. Progesterone support is less commonly given in natural cycles. A serum pregnancy test (beta-hCG) is performed 14 days after insemination.

IUI offers several important advantages that make it an appropriate first-line fertility intervention for many couples:

Minimally Invasive

IUI requires no sedation, no surgical egg retrieval, no embryo culture, and no embryo transfer under speculum — all hallmarks of IVF. The insemination itself takes under 10 minutes in the clinic and allows immediate return to normal activity. The physical and psychological burden is substantially lower than IVF.

Cost-Effective

A single IUI cycle costs approximately 10–20% of one IVF cycle. For couples likely to conceive within 3–4 IUI cycles, this represents a significant cost saving. In NHS-funded settings, IUI may be fully funded while IVF funding is subject to tighter eligibility criteria.

Cumulative Pregnancy Rates

Per-cycle pregnancy rates for stimulated IUI in unexplained infertility are typically 8–15% per cycle in women under 37 years with favourable parameters. Over 3–6 cycles, the cumulative pregnancy rate reaches 30–40%, representing a clinically meaningful and cost-efficient alternative to immediate IVF in appropriate patients.

For donor sperm IUI, per-cycle rates are somewhat higher (10–18%) reflecting optimal donor selection, giving cumulative rates of 45–60% over 6 cycles in women under 38.

Preserves Natural Fertilisation

Unlike IVF, IUI allows fertilisation to occur naturally in the fallopian tube, which some couples value as more physiological.

Bridges the Gap Before IVF

In healthcare systems with waiting lists or funding constraints for IVF, stimulated IUI provides active treatment while IVF eligibility criteria are met or while the couple awaits an IVF cycle start.

Acceptable Multiple Pregnancy Risk in Stimulated IUI

With careful monitoring and cycle cancellation when more than two mature follicles develop, the twin rate in stimulated IUI is approximately 10–15% — higher than natural conception (1–3%) but lower than IVF in the era of single embryo transfer (elective SET, <2%).

IUI is a safe procedure with a low risk profile, but patients must be counselled on both procedural risks and the limitations of the treatment in the context of their individual diagnosis.

Multiple Pregnancy (Stimulated Cycles)

The principal risk of stimulated IUI is multiple pregnancy. Twin pregnancies carry a 6-fold increased risk of premature birth and a doubled risk of pre-eclampsia compared with singleton pregnancies. High-order multiple pregnancy (triplets or more), while rare, carries serious risks for both mother and babies. Cycle cancellation when more than two mature follicles (>17 mm) are present is the primary risk-reduction strategy. Couples must accept cycle cancellation as a condition of treatment.

Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is substantially less common in IUI than in IVF, because the lower FSH doses used in IUI stimulation rarely produce more than three follicles. Mild OHSS (bloating, mild discomfort) occurs in approximately 1–3% of stimulated IUI cycles. Severe OHSS requiring hospitalisation is rare (<0.5%) in IUI. Patients with polycystic ovary syndrome (PCOS) are at higher risk and may require reduced FSH starting doses or metformin co-treatment.

Pelvic Infection

Introduction of the catheter through the cervix carries a theoretical risk of ascending infection into the uterus and fallopian tubes (pelvic inflammatory disease). In practice, rates are extremely low (<0.5%) in clinical IUI because the procedure is performed under aseptic conditions with a sterile single-use catheter. Prophylactic antibiotics are not routinely administered.

Failure to Conceive

The majority of IUI cycles do not result in pregnancy. Couples should be counselled about realistic cumulative success rates before starting treatment and should have a pre-agreed plan for what happens if IUI does not succeed within the planned number of cycles, including timely escalation to IVF.

NICE Guidance on Effectiveness

NICE NG156 explicitly states that unstimulated IUI offers no proven benefit over expectant management for unexplained infertility and should not be routinely offered. Couples with unexplained infertility who have been trying for over 2 years, or who are female-age 35 and above, should be counselled about direct IVF rather than IUI to avoid delay in accessing more effective treatment.

IUI cycles require careful monitoring and structured post-cycle review to optimise outcomes and make timely decisions about escalation.

During Stimulation (Stimulated Cycles)

Serial transvaginal ultrasound scans every 2–3 days from cycle day 8–10 monitor follicular growth and endometrial thickness. Serum oestradiol may be measured alongside ultrasound to assess follicular response. Scan results determine whether to continue stimulation at the current dose, increase the dose, administer the trigger injection, or cancel the cycle (if ovarian response is excessive — more than 3 mature follicles).

Luteal Phase (2-Week Wait)

The 14-day period between insemination and the pregnancy test is well recognised as psychologically challenging. Clinics should offer emotional support and clear written guidance on what symptoms are and are not associated with early pregnancy. Spotting (light bleeding) in the luteal phase can occur in early pregnancy (implantation bleeding) as well as in failed cycles and should not be interpreted as a definitive sign of failure.

Pregnancy Test

A serum beta-hCG blood test is performed 14 days after insemination. A positive result is followed by an ultrasound scan at 6–7 weeks gestation to confirm intrauterine location and number of gestational sacs (to identify multiple pregnancy early).

Failed Cycles: Review and Escalation

After each failed cycle, the clinical team should review the response data — follicle number, endometrial thickness, post-wash sperm parameters, and insemination timing — and consider whether any modifications are warranted for the next cycle. After 3–6 failed IUI cycles (depending on guideline and payer), a formal review appointment should be offered to discuss whether to continue IUI, escalate to IVF, or change diagnosis and approach entirely. Delays in escalating to IVF can have consequences in older patients where ovarian reserve is declining.

Emotional Support

Fertility treatment imposes significant emotional strain. Access to a fertility counsellor (mandatory under HFEA licensing requirements in UK registered clinics) should be offered proactively from the start of treatment, not only after failed cycles.

IUI is substantially less expensive than IVF and is the most cost-effective assisted reproduction technique per cycle. Costs vary significantly between countries and between NHS and private provision.

NHS Funding (United Kingdom)

NICE NG156 recommends that NHS Integrated Care Boards (ICBs) consider funding stimulated IUI cycles for eligible couples, particularly where IVF is not yet funded or where there are specific indications (donor sperm, single women, same-sex couples). In practice, NHS IUI funding varies widely by ICB — some fund up to 6 stimulated cycles, others have removed IUI from commissioned services entirely. Patients must check local ICB fertility funding policies.

Private Costs (United Kingdom)

A single private stimulated IUI cycle, including monitoring scans, medication, sperm wash, and insemination procedure, typically costs £900–£1,500. Unstimulated IUI is less expensive (£500–£800) as no FSH medication is required. Donor sperm adds £800–£1,500 per cycle (purchase, storage, and thaw costs).

International Pricing

• United States: $1,000–$3,000 per stimulated cycle including medication; donor sperm $500–$1,500 additional
• India (accredited clinics): ₹8,000–₹20,000 per cycle (approximately $100–$250), making India a significant medical tourism destination for IUI
• Spain: €600–€1,200 per cycle; popular with international patients due to liberal donor regulations
• Czech Republic: €400–€800 per cycle; widely used for donor insemination by patients across Europe

Cost vs Effectiveness Analysis

Cost-effectiveness modelling (National Institute for Health and Care Research, 2021) suggests that 3 cycles of stimulated IUI cost approximately the same as one IVF cycle, with similar cumulative pregnancy rates for women under 37 with unexplained infertility. For women aged 37–40, IVF becomes more cost-effective per live birth due to declining IUI success rates. This analysis should inform the IUI vs IVF decision for individual couples.

IUI sits between expectant management and IVF on the fertility treatment spectrum. Alternatives to consider depend on the underlying diagnosis, female age, and ovarian reserve:

Expectant Management (Timed Intercourse)

For couples with unexplained infertility of short duration (<2 years) where the woman is under 35, expectant management with or without ovulation tracking has a meaningful cumulative natural conception rate. NICE NG156 recommends up to 2 years of expectant management in suitable couples before proceeding to stimulated IUI or IVF.

Ovulation Induction with Timed Intercourse

For women with anovulatory cycles (polycystic ovary syndrome, hypothalamic amenorrhoea), ovulation induction with clomifene or letrozole combined with timed intercourse is often more appropriate than IUI as a first-line approach. NICE recommends letrozole over clomifene for anovulatory PCOS based on superior live birth and singleton rates (PCOSMIC trial).

IVF (In Vitro Fertilisation)

IVF is more effective per cycle than IUI for most diagnoses and should be offered earlier for: women over 37; couples with more than mild male factor; low ovarian reserve (AMH <1.0 ng/mL); more than 3–6 failed IUI cycles; and all cases of tubal factor infertility. The NICE NG156 recommendation is that couples should not be delayed through multiple IUI cycles when IVF is clearly more appropriate based on their individual profile.

IVF with ICSI

For severe male factor infertility (TMSC post-wash <5 million, or high rates of abnormal morphology) that is insufficient for IUI, intracytoplasmic sperm injection (ICSI) — where a single sperm is injected directly into each egg — delivers dramatically higher fertilisation rates than either IUI or conventional IVF insemination.

Donor Egg IVF

For women with very poor ovarian reserve (AMH <0.5 ng/mL) or premature ovarian insufficiency, donor egg IVF circumvents ovarian reserve limitations and achieves pregnancy rates of 40–50% per cycle based on donor egg quality rather than recipient age.